A recent study published in Nature Medicine highlights the long-term benefits of Wegovy for diabetes, heart disease, and weight loss. The findings suggest that these benefits can last up to four years, providing new insight into preventing rebound weight gain, a common side effect of stopping GLP-1 drugs for weight loss. GLP-1 agonists like Ozempic and Wegovy have gained popularity for weight loss in recent years, with 1 in 8 people in the United States having taken these medications for weight loss. Traditionally used to treat diabetes and heart disease, these drugs have proven effective for weight management and maintaining weight loss for at least four years.
The SELECT trial, which included more than 17,000 adults with overweight or obesity who did not have diabetes, found an average 4-year weight loss of -10.2% of initial weight, a reduction in waist circumference, and a reduced waist-to-height ratio compared to people taking a placebo. Despite common belief that weight loss plateaus once a person stops taking GLP-1 agonists, recent studies have shown that tapering down dosage or combining medications with exercise can help patients maintain weight loss. Dr. Cheng-Han Chen and Dr. Mir Ali highlight the importance of understanding weight loss plateaus and the need for ongoing support and monitoring to maintain weight loss over time.
GLP-1 agonists mimic the body’s natural hormone, slowing the passage of food in the digestive tract and reducing appetite. These drugs have slightly different mechanisms of action based on their chemical composition, with different products such as Wegovy, Ozempic, and Rybelsus containing semaglutide, and others like Saxenda and Victoza containing liraglutide. In addition to weight loss benefits, GLP-1 medications help manage diabetes by increasing insulin production after meals, helping control blood sugar levels. Studies have also shown potential cardiovascular benefits of these drugs, with a trial demonstrating a 20% decrease in adverse cardiovascular events in people taking Ozempic compared to a control group.
While only Wegovy is approved for weight loss, other GLP-1 drugs are similarly effective and approved for diabetes and heart health. Pharmaceutical companies have faced challenges in meeting the high demand for these medications, with the cost being a significant barrier for patients. The list price for a month’s supply of Wegovy is $1,349.02 and $935.77 for Ozempic, making them costly options for those without adequate insurance coverage. Despite the potential cost savings in resolving conditions like diabetes and high blood pressure, insurance coverage for weight-loss medications remains limited. Continued research and data supporting the cost-saving benefits of these medications may eventually lead to broader insurance coverage for weight-loss treatments like GLP-1 agonists.
